In patients with type 2 diabetes (T2D), the use of GLP-1 receptor agonists (RAs) is not associated with an increased risk for most serious gastrointestinal (GI) or hepatobiliary outcomes over 5 years, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback